Skip to main content
. 2020 Mar 23;12(3):758. doi: 10.3390/cancers12030758

Figure 3.

Figure 3

Abrogation of MeCP2 inhibits colorectal cancer (CRC) cell migration, invasion, and stemness. (A) MeCP2 knockdown and knockout inhibited HCT116 cell migration and invasion in a Transwell assay. Representative images (left) and quantitative analyses (right) are shown. (B) MeCP2 knockdown and knockout inhibited SW480 cell migration and invasion in a Transwell assay. Representative images (left) and quantitative analyses (right) are shown. (C) Knockout of MeCP2 in HCT116 cells suppressed migration in a wound-healing assay. Representative images are shown. (D) Knockout of MeCP2 in SW480 cells suppressed migration in a wound-healing assay. Representative images are shown. (E,F) Representative images and quantification of the in vitro sphere-formation assay of MeCP2 knockout in CRC cells and control cells (n = 6). P1: Passage 1, P2: Passage 2, P3: Passage 3. Scale bar: 200 µm. * p < 0.05, ** p < 0.01, *** p < 0.001 (Student’s t-test).